247 filings
Page 3 of 13
8-K
pshu1x9
29 Jul 21
Seagen Reports Second Quarter 2021 Financial Results
4:04pm
8-K
hm9ifvv
15 Jul 21
Entry into a Material Definitive Agreement
4:23pm
8-K
6e6642d
9 Jul 21
Other Events
5:17pm
8-K
d6bumjh
25 Jun 21
Entry into a Material Definitive Agreement
4:34pm
8-K
xjlb 9yzb9bma
19 May 21
Submission of Matters to a Vote of Security Holders
4:49pm
8-K
df5h jk86dc5i
29 Apr 21
Seagen Reports First Quarter 2021 Financial Results
4:03pm
8-K
ubn0bdg wk37a0e
11 Feb 21
Seagen Reports Fourth Quarter and Full Year 2020 Financial Results
4:06pm
8-K
sr4 s3p85e5z9avo
29 Dec 20
Other Events
4:15pm
8-K
06d6gwzae5tln
29 Oct 20
Seagen Reports Third Quarter 2020 Financial Results
4:08pm
8-K
mt70t
20 Oct 20
Regulation FD Disclosure
6:04am
8-K
d9v31z1whhoyl8mz
13 Oct 20
Other Events
7:31am
8-K
yeegywta04hbo
8 Oct 20
Amendments to Articles of Incorporation or Bylaws
8:28am
8-K
6mpx5 x85
18 Sep 20
Significantly Improved Overall Survival in Phase 3 Trial in Previously
6:59am
8-K
e0q zlalm
14 Sep 20
Entry into a Material Definitive Agreement
6:57am
8-K
684rvr do
18 Aug 20
Seattle Genetics Appoints Ted W. Love, M.D., to Board of Directors
8:11am
8-K
vqlug f1sl
31 Jul 20
Seattle Genetics Reports Second Quarter 2020 Financial Results
7:44am
8-K
94hfmzki7179k1
29 Jun 20
Seattle Genetics Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
12:00am
8-K
vkfg 7jk4gkn
19 May 20
Departure of Directors or Certain Officers
5:02pm
8-K
ml18tqf
30 Apr 20
Seattle Genetics Reports First Quarter 2020 Financial Results
4:07pm
8-K
4q2ukh3xt axd
17 Apr 20
Entry into a Material Definitive Agreement
4:33pm